COLUMBUS, Ohio (WCMH) — When you go to a brand-new Columbus Metropolitan Library (CML) branch, you’ll notice it’s not just the usual giant rows of books as you’d expect. The changes are intentional, ...

Terns Pharmaceuticals (TERN) has suddenly landed on many investors radar after reporting encouraging CARDINAL trial data for its CML pill, with major molecular response rates and cancer cell ...

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...

Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

CML Unlocks AI’s Full Potential with Enhanced Pattern Recognition, Prediction, and Real-Time Decision-Making for Defense, Autonomous Systems, and Next-Gen Computing BOULDER, Colo.--(BUSINESS ...

COLUMBUS, Ohio — In Columbus, a truck decorated with colorful geometric shapes and filled with dozens of books will soon deliver the library straight to readers. The Columbus Metropolitan Library is ...

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday, the FDA ...

The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...